Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced … Recruiting

2023-509846-36-00 Advanced Solid Tumors 2020-05-29
Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with… Recruiting

2024-511523-33-00 Fanconi anemia (subtype A) 2020-05-28
A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advance… Recruiting

2024-510712-75-00 advanced / metastatic 2020-02-12
MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib Recruiting

2024-513766-20-00 Hematological malignancies 2019-12-03
Investigation of cardiac metabolism in patients with heart failure using hyperpolarized MRI Recruiting

2024-515414-40-00 Heart failure 2019-12-01
A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting

2023-509699-41-00 Recurrent or Refractory Leukemias, Lymphomas, and Solid 2019-11-22
Glioblastoma treatment with irradiation and olaptesed pegol (NOX-A12) in unmethylated patients Recruiting

2024-510964-21-00 Glioblastoma 2019-09-12
INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-… Recruiting

2024-514409-78-01 relapsed / refractory or progressive high risk malignan 2019-07-26
A clinical study to evaluate the safety, tolerability and early efficacy of the study drug (Durvalumab) alone and a combination of study dru… Recruiting

2023-510424-68-00 Advanced Solid Tumors 2019-05-28
An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting

2024-515690-10-00 Follicular B-cell non-Hodgkin's lymphoma 2019-05-10
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retrovir… Recruiting

2024-516832-82-00 Accute lymphoblastic leukemia recurrent, Non-Hodgkin´s 2018-08-27
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting

2023-503629-20-00 Metastatic breast cancer, including triple negative bre 2018-06-27
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting

2023-504880-18-00 Neuroblastoma (NBL) 2018-04-18
A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / … Recruiting

2024-517094-24-00 Solid tumors 2018-01-08
A Phase 1/2a gene therapy clinical trial in Retinitis Pigmentosa subjects. Recruiting

2024-516059-42-00 Retinitis Pigmentosa 2017-12-22
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Metastatic Castration-Resistant Prostate Cancer 2016-11-17
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 pediatric cancer 2016-08-03
VICTORIA (hormone receptor postiVe endometrIal Carcinoma treated by dual mTORC1/mTORC2 Inhibitor and Anastrozole):A Multicentric, randomized… Recruiting

2024-516725-31-00 advanced and metastatic 2016-04-14
A Phase I/II trial of MK-3475 (pembrolizumab) in children's solid tumors and lymphoma Recruiting

2022-501257-36-00 Treatment of advanced melanoma, or advanced, relapsed o 2015-03-19
VshoRT-R3: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperatIve treatment in low-moderate risk r… Recruiting

2024-513920-40-00 low- risk rectal cancel 2013-01-11
A Phase 1/2 Study with Ascending Dose in order to Evaluate the Safety and Effects on Progranulin Levels of investigational product under cod… Ended

2022-502942-29-01 Fronto-Temporal Dementia with Progranulin Mutations (FT 2026-03-23
A Phase 1/2 Study to Evaluate ALN-6400 in Adult Healthy Volunteers and Adult Patients with HHT Ended

2025-522510-23-00 Hereditary Hemorrhagic Telangiectasia (HHT) 2025-12-15
IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS Ended

2023-506478-11-01 chronic kidney disease 2025-08-28
A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairT… Ended

2023-504909-37-00 Cystic fibrosis 2025-07-03